 Enzyme Inhibitors
"Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
| Descriptor ID |
D004791
|
| MeSH Number(s) |
D27.505.519.389
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Inhibitors".
This graph shows the total number of publications written about "Enzyme Inhibitors" by people in this website by year, and whether "Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 4 | 6 | | 1996 | 5 | 12 | 17 | | 1997 | 6 | 19 | 25 | | 1998 | 3 | 15 | 18 | | 1999 | 8 | 18 | 26 | | 2000 | 6 | 27 | 33 | | 2001 | 10 | 34 | 44 | | 2002 | 11 | 46 | 57 | | 2003 | 10 | 32 | 42 | | 2004 | 9 | 35 | 44 | | 2005 | 8 | 19 | 27 | | 2006 | 7 | 20 | 27 | | 2007 | 12 | 15 | 27 | | 2008 | 11 | 21 | 32 | | 2009 | 10 | 22 | 32 | | 2010 | 9 | 17 | 26 | | 2011 | 10 | 9 | 19 | | 2012 | 12 | 20 | 32 | | 2013 | 5 | 19 | 24 | | 2014 | 10 | 14 | 24 | | 2015 | 6 | 12 | 18 | | 2016 | 7 | 9 | 16 | | 2017 | 6 | 5 | 11 | | 2018 | 9 | 6 | 15 | | 2019 | 2 | 8 | 10 | | 2020 | 6 | 3 | 9 | | 2021 | 6 | 1 | 7 | | 2022 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Enzyme Inhibitors" by people in Profiles.
-
Crawley WT, Jungels CG, Stenmark KR, Fini MA. U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia. Redox Biol. 2022 05; 51:102271.
-
Tian D, Han M. Bacterial peptidoglycan muropeptides benefit mitochondrial homeostasis and animal physiology by acting as ATP synthase agonists. Dev Cell. 2022 02 07; 57(3):361-372.e5.
-
Hongdusit A, Liechty ET, Fox JM. Analysis of Three Architectures for Controlling PTP1B with Light. ACS Synth Biol. 2022 01 21; 11(1):61-68.
-
Anantharajan J, Baburajendran N, Lin G, Loh YY, Xu W, Ahmad NHB, Liu S, Jansson AE, Kuan JWL, Ng EY, Yeo YK, Hung AW, Joy J, Hill J, Ford HL, Zhao R, Keller TH, Kang C. Structure-activity relationship studies of allosteric inhibitors of EYA2 tyrosine phosphatase. Protein Sci. 2022 02; 31(2):422-431.
-
Ligezka AN, Radenkovic S, Saraswat M, Garapati K, Ranatunga W, Krzysciak W, Yanaihara H, Preston G, Brucker W, McGovern RM, Reid JM, Cassiman D, Muthusamy K, Johnsen C, Mercimek-Andrews S, Larson A, Lam C, Edmondson AC, Ghesquière B, Witters P, Raymond K, Oglesbee D, Pandey A, Perlstein EO, Kozicz T, Morava E. Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic Implications. Ann Neurol. 2021 12; 90(6):887-900.
-
Gautam D, Pedler MG, Nair DP, Petrash JM. Nanogel-Facilitated In-Situ Delivery of a Cataract Inhibitor. Biomolecules. 2021 08 04; 11(8).
-
Casalvieri KA, Matheson CJ, Warfield BM, Backos DS, Reigan P. N-Substituted pyrrolopyrimidines and purines as p90 ribosomal S6 protein kinase-2 (RSK2) inhibitors. Bioorg Med Chem. 2021 07 01; 41:116220.
-
Sarkar A, Kim EY, Jang T, Hongdusit A, Kim H, Choi JM, Fox JM. Microbially Guided Discovery and Biosynthesis of Biologically Active Natural Products. ACS Synth Biol. 2021 06 18; 10(6):1505-1519.
-
Rogawski DS, Deng J, Li H, Miao H, Borkin D, Purohit T, Song J, Chase J, Li S, Ndoj J, Klossowski S, Kim E, Mao F, Zhou B, Ropa J, Krotoska MZ, Jin Z, Ernst P, Feng X, Huang G, Nishioka K, Kelly S, He M, Wen B, Sun D, Muntean A, Dou Y, Maillard I, Cierpicki T, Grembecka J. Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity. Nat Commun. 2021 05 14; 12(1):2792.
-
Verbsky JW, Hintermeyer MK, Simpson PM, Feng M, Barbeau J, Rao N, Cool CD, Sosa-Lozano LA, Baruah D, Hammelev E, Busalacchi A, Rymaszewski A, Woodliff J, Chen S, Bausch-Jurken M, Routes JM. Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency. J Allergy Clin Immunol. 2021 02; 147(2):704-712.e17.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|